Bubs share price: Citi says ‘buy’ and a capital raise is announced

The company's stock has today been put in a trading halt, as an announcement pending a planned capital raise is set to be revealed to the market.

Capital raise announced

Bubs’ (ASX: BUB) shares have today been put in a trading halt, as the fast-growing infant formula company revealed that it was planning on pursuing a capital raise.

Bubs now joins a raft of ASX-listed companies – including Afterpay, Zip, Westpac and the Bank of Queensland – tapping the markets for fresh capital.

While no specific details of the Bubs capital raise have been announced just yet – one can speculate that Bubs would likely used any funds derived from a potential capital raise to further ramp up its growth plans.

Indeed, FY19 already proved to be a record growth year for the young company: with gross revenue rising 154% to $46.8m. In step with this, and maybe even more impressively, Bubs China Net revenue grew 209% in FY19.

In line with this explosive growth profile, the Bubs share price has more than doubled in CY19 – rising 135% since January.

Practise trading Australian stocks with an IG demo account now

Bubs share price: Citi says ‘buy’

The announcement of a planned cap raise comes just one day after investment giant Citibank initiated coverage on the infant formula player: hitting Bubs (ASX: BUB) with a buy rating and a 12-month share price target of $1.40.

At Bubs’ (ASX: BUB) last traded price, this would imply potential upside of a little over 30%.

Centrally, Citi posits that Bubs is well-positioned to capitalise on the premiumisation trend sweeping the Chinese infant formula market (IMF) – and as a result of this – sees substantial top and bottom-line growth opportunities for the company in the coming years. Funds derived from the planned capital raise would likely help further any such plans.

In saying that, the investment bank has flagged a number of risks to their investment thesis, noting that an investment in Bubs remains 'high risk.' Fundamentally, these risks include the fact that Bubs remains loss-making, competition remains intense and the possibility that Bubs will be unable to adequately capitalise on the significant opportunities at hand.

Citi further points out that Bubs’ current valuation suggests that the market is expecting big things from the young company.

Ultimately, Citi believes that the prospect of Bubs’ fundamentals catching up with the market's current growth expectations by FY22 is not ‘unrealistic’ – as the company potentially transitions to profitability. On this front, the investment bank expects Bubs to achieve profitability in FY21 – with forecasted profits (core NPAT) of $10.4m.


IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
Bid
Offer
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Bid
Offer
Updated
Change

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Bid
Offer
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
China 300
-
-
-
-

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.